October 20 Daily Buzz at ACR 2018

Liz Neporent

October 20, 2018

Getting ready for the start of ACR 2018 at the McCormick Place conference center in Chicago


CHICAGO — The American College of Rheumatology (ACR) 2018 Annual Meeting is now underway in Chicago. More than 16,000 attendees, including rheumatologists, health professionals, fellows-in-training, and exhibitors, from more than 100 countries have gathered in the windy city to focus on new developments in rheumatology.


Here's What We're Waiting For

Clinical trial results will be unveiled on Sunday and a study looking at influenza vaccine doses for patients with rheumatoid arthritis is highly anticipated. Patients with autoimmune diseases are at increased risk for infection and complications from the flu and are therefore a high-priority population for annual vaccination.

Another trial of interest will assess inappropriate pain management in adults with osteoporosis who are treated with different opioid regiments. Researchers from Tufts University in Medford, Massachusetts will take a retrospective look at patterns of opioid prescription in more than 200,000 patients with hip osteoporosis, knee osteoporosis, or both.

Conference attendees are already debating hot topics from the conference on social media. They've fired off nearly 950 tweets under the official #ACR18 hashtag in the past 24 hours, and more than 450 users have joined the conversation.

Unexpected Conversation

Gout is a surprisingly hot topic online, perhaps because of an upcoming presentation that will show that all-cause hospitalizations for gout patients have increased an astonishing 410% in 22 years.

There is also a lively twitter thread discussing some exciting research on the use of wearables to track gout symptoms. This will be presented as part of a larger session on wearables in rheumatology clinical practice and rehabilitation.


Follow all of Medscape's coverage on the ACR 2018 conference page and on our Twitter, Instagram and Facebook accounts.

Follow Medscape Rheumatology on Twitter @MedscapeRheum and Liz Neporent @LizzyFit



Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: